secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250698
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics sells avasopasem and rucosopasem assets to Biossil Inc.
---------------------------------------------------------------------------

- Sold all dismutase mimetic assets including avasopasem (GC4419) and rucosopasem (GC4711) to Biossil Inc., a Canadian company.
- Transaction closed Oct 15, 2025; Blackstone Agreement assigned to Biossil on Oct 21, 2025.
- Blackstone will look solely to Biossil for all obligations under the Amended Blackstone Agreement; Galera relieved of those liabilities.
- No purchase price or deal financial terms disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312525250698/0001193125-25-250698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312525250698/d904873d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer